| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 23 | 2022 | 164 | 2.370 |
Why?
|
| Cardiac Catheterization | 20 | 2014 | 247 | 1.550 |
Why?
|
| Angioplasty, Balloon, Coronary | 26 | 2014 | 161 | 1.510 |
Why?
|
| Angioplasty | 4 | 2012 | 47 | 0.890 |
Why?
|
| Coronary Angiography | 19 | 2015 | 172 | 0.760 |
Why?
|
| Heart Valve Prosthesis Implantation | 8 | 2014 | 155 | 0.720 |
Why?
|
| Stents | 7 | 2010 | 450 | 0.660 |
Why?
|
| Coronary Disease | 14 | 2002 | 249 | 0.600 |
Why?
|
| Coronary Artery Disease | 9 | 2015 | 272 | 0.580 |
Why?
|
| Clinical Competence | 11 | 2014 | 685 | 0.540 |
Why?
|
| Hospitals | 6 | 2014 | 376 | 0.500 |
Why?
|
| Societies, Medical | 11 | 2013 | 331 | 0.490 |
Why?
|
| Myocardial Infarction | 9 | 2009 | 862 | 0.460 |
Why?
|
| Coronary Vessels | 8 | 2012 | 109 | 0.460 |
Why?
|
| Coronary Artery Bypass | 10 | 2010 | 274 | 0.430 |
Why?
|
| Mitral Valve | 4 | 2014 | 104 | 0.430 |
Why?
|
| Heart Valve Diseases | 4 | 2014 | 88 | 0.420 |
Why?
|
| Aortic Valve Stenosis | 5 | 2014 | 172 | 0.420 |
Why?
|
| Patient Selection | 7 | 2011 | 448 | 0.390 |
Why?
|
| Cardiovascular Agents | 3 | 2007 | 101 | 0.350 |
Why?
|
| Patient Care Team | 8 | 2014 | 333 | 0.310 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 105 | 0.310 |
Why?
|
| Radiology, Interventional | 3 | 2011 | 29 | 0.290 |
Why?
|
| Thrombolytic Therapy | 5 | 2007 | 182 | 0.290 |
Why?
|
| Treatment Outcome | 22 | 2022 | 5205 | 0.290 |
Why?
|
| Medical Informatics | 1 | 2008 | 68 | 0.280 |
Why?
|
| Patient Education as Topic | 2 | 2008 | 446 | 0.280 |
Why?
|
| Humans | 70 | 2022 | 59817 | 0.280 |
Why?
|
| Quality Assurance, Health Care | 3 | 2014 | 248 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 709 | 0.260 |
Why?
|
| Attitude of Health Personnel | 2 | 2007 | 563 | 0.260 |
Why?
|
| Thrombosis | 2 | 2007 | 190 | 0.250 |
Why?
|
| Public Health | 1 | 2007 | 180 | 0.250 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 252 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2007 | 743 | 0.250 |
Why?
|
| Health Policy | 3 | 2016 | 185 | 0.240 |
Why?
|
| Coitus | 1 | 2004 | 15 | 0.230 |
Why?
|
| Internet | 1 | 2008 | 460 | 0.230 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 392 | 0.220 |
Why?
|
| Risk Assessment | 11 | 2015 | 1918 | 0.210 |
Why?
|
| American Heart Association | 6 | 2014 | 128 | 0.210 |
Why?
|
| Health Promotion | 1 | 2007 | 490 | 0.210 |
Why?
|
| Evidence-Based Medicine | 8 | 2012 | 454 | 0.210 |
Why?
|
| Obesity, Morbid | 1 | 2004 | 92 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2022 | 41 | 0.190 |
Why?
|
| United States | 15 | 2016 | 7569 | 0.180 |
Why?
|
| Program Development | 4 | 2014 | 211 | 0.180 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2010 | 60 | 0.180 |
Why?
|
| Ambulatory Care | 2 | 2015 | 306 | 0.170 |
Why?
|
| Risk Factors | 11 | 2011 | 5040 | 0.170 |
Why?
|
| Cardiovascular Diseases | 4 | 2010 | 830 | 0.170 |
Why?
|
| Coronary Thrombosis | 2 | 2007 | 19 | 0.170 |
Why?
|
| Radiography, Interventional | 2 | 2011 | 70 | 0.170 |
Why?
|
| Occupational Exposure | 3 | 2011 | 309 | 0.160 |
Why?
|
| Women's Health | 3 | 2015 | 390 | 0.160 |
Why?
|
| Hemorrhage | 2 | 2000 | 269 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 4 | 2013 | 92 | 0.160 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 33 | 0.160 |
Why?
|
| Postoperative Complications | 4 | 2012 | 1142 | 0.160 |
Why?
|
| Registries | 7 | 2010 | 804 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2007 | 214 | 0.150 |
Why?
|
| Myocardial Revascularization | 4 | 2010 | 71 | 0.150 |
Why?
|
| Male | 36 | 2013 | 27771 | 0.150 |
Why?
|
| Quality of Health Care | 6 | 2012 | 524 | 0.150 |
Why?
|
| Middle Aged | 28 | 2015 | 16402 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 1999 | 251 | 0.140 |
Why?
|
| Health Facilities | 2 | 2014 | 43 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2011 | 426 | 0.130 |
Why?
|
| Female | 34 | 2015 | 31100 | 0.130 |
Why?
|
| Medical Staff Privileges | 5 | 2014 | 9 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 116 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2013 | 137 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 141 | 0.120 |
Why?
|
| Abnormalities, Radiation-Induced | 2 | 2011 | 2 | 0.120 |
Why?
|
| Radiation Monitoring | 2 | 2011 | 5 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2011 | 26 | 0.110 |
Why?
|
| Certification | 1 | 2014 | 49 | 0.110 |
Why?
|
| Radiation Protection | 2 | 2011 | 24 | 0.110 |
Why?
|
| Time Factors | 8 | 2012 | 3590 | 0.110 |
Why?
|
| Fetus | 2 | 2011 | 97 | 0.110 |
Why?
|
| Electrocardiography | 5 | 2009 | 524 | 0.110 |
Why?
|
| Radiation Dosage | 2 | 2011 | 127 | 0.110 |
Why?
|
| Documentation | 1 | 2014 | 129 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2013 | 13 | 0.110 |
Why?
|
| Sex Factors | 6 | 2010 | 968 | 0.100 |
Why?
|
| Prosthesis Design | 3 | 2010 | 206 | 0.100 |
Why?
|
| Angiography | 4 | 2004 | 145 | 0.100 |
Why?
|
| Patient Care | 1 | 2013 | 78 | 0.100 |
Why?
|
| Knowledge Bases | 4 | 2012 | 4 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2007 | 681 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 1991 | 24 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 2 | 2010 | 87 | 0.090 |
Why?
|
| Thoracic Injuries | 1 | 1991 | 47 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 330 | 0.090 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1991 | 16 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1991 | 102 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 168 | 0.090 |
Why?
|
| Saphenous Vein | 1 | 2010 | 45 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 98 | 0.090 |
Why?
|
| Algorithms | 1 | 2015 | 998 | 0.090 |
Why?
|
| Heart Atria | 1 | 1991 | 138 | 0.090 |
Why?
|
| Length of Stay | 4 | 2009 | 771 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1991 | 75 | 0.080 |
Why?
|
| Career Choice | 3 | 2022 | 111 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 659 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2010 | 31 | 0.080 |
Why?
|
| Women | 1 | 2010 | 46 | 0.080 |
Why?
|
| Stroke | 2 | 2010 | 1143 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 569 | 0.080 |
Why?
|
| Aged | 20 | 2012 | 13463 | 0.080 |
Why?
|
| Pregnancy | 3 | 2011 | 2360 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 164 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 1991 | 120 | 0.080 |
Why?
|
| Occupational Health | 1 | 2011 | 186 | 0.080 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 925 | 0.080 |
Why?
|
| Atherectomy, Coronary | 3 | 2003 | 13 | 0.080 |
Why?
|
| Follow-Up Studies | 9 | 2002 | 2341 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2011 | 266 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1460 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2012 | 422 | 0.070 |
Why?
|
| Oxygen | 1 | 2009 | 309 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 298 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2007 | 41 | 0.070 |
Why?
|
| Drug-Eluting Stents | 1 | 2007 | 54 | 0.070 |
Why?
|
| Contrast Media | 1 | 2009 | 414 | 0.070 |
Why?
|
| Peptides | 2 | 2002 | 546 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 42 | 0.070 |
Why?
|
| Coronary Restenosis | 2 | 2003 | 18 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 1030 | 0.070 |
Why?
|
| Myocardial Ischemia | 3 | 2002 | 109 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 332 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2015 | 3110 | 0.060 |
Why?
|
| Advisory Committees | 3 | 2013 | 107 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2000 | 485 | 0.060 |
Why?
|
| Observer Variation | 2 | 2012 | 201 | 0.060 |
Why?
|
| Fibrinolytic Agents | 2 | 2000 | 164 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2009 | 480 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 173 | 0.060 |
Why?
|
| Credentialing | 1 | 2005 | 15 | 0.060 |
Why?
|
| Vascular Patency | 3 | 2010 | 132 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 62 | 0.060 |
Why?
|
| Oximes | 2 | 1994 | 11 | 0.060 |
Why?
|
| Organotechnetium Compounds | 2 | 1994 | 28 | 0.060 |
Why?
|
| Adult | 9 | 2011 | 15882 | 0.050 |
Why?
|
| Cholesterol | 2 | 2002 | 255 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 26 | 0.050 |
Why?
|
| Physicians | 1 | 2008 | 437 | 0.050 |
Why?
|
| Echocardiography | 2 | 1999 | 459 | 0.050 |
Why?
|
| Angioplasty, Balloon | 1 | 2002 | 58 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2002 | 84 | 0.050 |
Why?
|
| Retirement | 1 | 2022 | 17 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 909 | 0.050 |
Why?
|
| Stroke Volume | 3 | 2001 | 321 | 0.050 |
Why?
|
| Angina Pectoris | 4 | 2002 | 36 | 0.050 |
Why?
|
| Career Mobility | 1 | 2022 | 62 | 0.050 |
Why?
|
| Heparin | 2 | 1999 | 111 | 0.050 |
Why?
|
| Hemodynamics | 3 | 1996 | 235 | 0.050 |
Why?
|
| Survival Rate | 2 | 2000 | 790 | 0.050 |
Why?
|
| Disease Management | 2 | 2013 | 220 | 0.050 |
Why?
|
| Pain | 1 | 2004 | 406 | 0.050 |
Why?
|
| Streptokinase | 1 | 2000 | 6 | 0.040 |
Why?
|
| Platelet Count | 1 | 2000 | 25 | 0.040 |
Why?
|
| Curriculum | 2 | 2013 | 563 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2014 | 249 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2000 | 73 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2010 | 32 | 0.040 |
Why?
|
| Benchmarking | 2 | 2011 | 135 | 0.040 |
Why?
|
| Shock, Cardiogenic | 1 | 2000 | 85 | 0.040 |
Why?
|
| Diffusion of Innovation | 2 | 2010 | 56 | 0.040 |
Why?
|
| Constriction, Pathologic | 3 | 1994 | 104 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2000 | 125 | 0.040 |
Why?
|
| Consensus | 2 | 2011 | 195 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 83 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1998 | 120 | 0.040 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 313 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1998 | 64 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 374 | 0.040 |
Why?
|
| Age Factors | 1 | 2000 | 1519 | 0.030 |
Why?
|
| Rest | 1 | 1994 | 43 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1994 | 69 | 0.030 |
Why?
|
| Fish Oils | 1 | 1994 | 43 | 0.030 |
Why?
|
| Diastole | 1 | 1994 | 89 | 0.030 |
Why?
|
| Policy Making | 1 | 2014 | 51 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1994 | 50 | 0.030 |
Why?
|
| Educational Status | 1 | 1995 | 273 | 0.030 |
Why?
|
| Incidence | 2 | 2002 | 1245 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1994 | 577 | 0.030 |
Why?
|
| Radiography | 1 | 1995 | 513 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 23 | 0.030 |
Why?
|
| Foundations | 1 | 2013 | 8 | 0.030 |
Why?
|
| Research Report | 1 | 2013 | 28 | 0.030 |
Why?
|
| Logistic Models | 3 | 2002 | 1252 | 0.030 |
Why?
|
| Education, Medical | 2 | 2010 | 178 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 707 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 442 | 0.020 |
Why?
|
| Health Physics | 1 | 2011 | 6 | 0.020 |
Why?
|
| X-Rays | 1 | 2011 | 44 | 0.020 |
Why?
|
| Argentina | 1 | 2010 | 6 | 0.020 |
Why?
|
| Radiometry | 1 | 2011 | 35 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 142 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2002 | 233 | 0.020 |
Why?
|
| Research Subjects | 1 | 1991 | 38 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 89 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1991 | 100 | 0.020 |
Why?
|
| Swine | 2 | 1994 | 349 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 158 | 0.020 |
Why?
|
| Informed Consent | 1 | 1991 | 133 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2009 | 41 | 0.020 |
Why?
|
| Troponin | 1 | 2009 | 37 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 385 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2461 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 30 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1989 | 30 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1989 | 17 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 106 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1989 | 38 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 43 | 0.020 |
Why?
|
| Mentors | 1 | 2010 | 118 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2010 | 204 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1989 | 101 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 134 | 0.020 |
Why?
|
| Quality of Life | 1 | 1995 | 1129 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 798 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 209 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 2002 | 105 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 95 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 171 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 716 | 0.020 |
Why?
|
| Child | 1 | 1996 | 4324 | 0.020 |
Why?
|
| Recurrence | 3 | 1994 | 580 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 1985 | 12 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1985 | 56 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 543 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 111 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 1205 | 0.010 |
Why?
|
| Prosthesis Implantation | 1 | 2003 | 30 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 279 | 0.010 |
Why?
|
| Belgium | 1 | 2002 | 6 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 78 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 317 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 523 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 19722 | 0.010 |
Why?
|
| Triglycerides | 1 | 2002 | 241 | 0.010 |
Why?
|
| Prognosis | 2 | 2002 | 1584 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1994 | 679 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 466 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 659 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 486 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 160 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 927 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 553 | 0.010 |
Why?
|
| Emergency Treatment | 1 | 2000 | 51 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 672 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 189 | 0.010 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1999 | 3 | 0.010 |
Why?
|
| Emergencies | 1 | 2000 | 114 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2002 | 6040 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 154 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 169 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1999 | 61 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 279 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1998 | 39 | 0.010 |
Why?
|
| Massachusetts | 1 | 2002 | 2112 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2000 | 847 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1995 | 59 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 116 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 104 | 0.010 |
Why?
|
| Heart Failure | 1 | 2000 | 868 | 0.010 |
Why?
|
| Heart | 1 | 1994 | 276 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1995 | 424 | 0.010 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1991 | 5 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1993 | 191 | 0.010 |
Why?
|
| Consent Forms | 1 | 1991 | 15 | 0.010 |
Why?
|
| Forecasting | 1 | 1992 | 221 | 0.010 |
Why?
|
| Reoperation | 1 | 1992 | 257 | 0.010 |
Why?
|
| Comprehension | 1 | 1991 | 128 | 0.010 |
Why?
|
| Smoking | 1 | 1994 | 830 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1989 | 19 | 0.010 |
Why?
|
| Perfusion | 1 | 1986 | 77 | 0.000 |
Why?
|
| Bepridil | 1 | 1985 | 1 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 18 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1985 | 34 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1985 | 44 | 0.000 |
Why?
|
| Heart Rate | 1 | 1985 | 306 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1985 | 522 | 0.000 |
Why?
|